Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track ...
FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy, expanding systemic options beyond injectables.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results